Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 17 SEER Areas, 2006-2008

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	38.08 (37.96, 38.21)	38.83 (38.69, 38.97)	33.43 (33.06, 33.80)
Invasive and In Situ	41.38 (41.25, 41.51)	42.17 (42.03, 42.31)	35.73 (35.34, 36.11)
Oral Cavity and Pharynx	0.67 (0.65, 0.68)	0.68 (0.66, 0.70)	0.47 (0.43, 0.52)
Esophagus	0.24 (0.23, 0.25)	0.24 (0.23, 0.25)	0.27 (0.24, 0.31)
Stomach	0.67 (0.66, 0.69)	0.57 (0.55, 0.59)	0.96 (0.89, 1.03)
Colon and Rectum	4.91 (4.87, 4.96)	4.84 (4.79, 4.89)	5.15 (5.00, 5.30)
Invasive and In Situ	5.12 (5.07, 5.16)	5.02 (4.97, 5.07)	5.44 (5.29, 5.60)
Liver and Intrahepatic Bile Duct	0.49 (0.47, 0.50)	0.42 (0.40, 0.43)	0.47 (0.43, 0.52)
Pancreas	1.45 (1.42, 1.47)	1.42 (1.39, 1.44)	1.66 (1.58, 1.75)
Larynx	0.14 (0.13, 0.15)	0.15 (0.14, 0.15)	0.17 (0.15, 0.20)
Invasive and In Situ	0.15 (0.14, 0.16)	0.16 (0.15, 0.17)	0.18 (0.15, 0.20)
Lung and Bronchus	6.33 (6.28, 6.39)	6.64 (6.59, 6.70)	5.56 (5.41, 5.71)
Melanoma of the Skin	1.57 (1.55, 1.59)	1.83 (1.80, 1.86)	0.09 (0.07, 0.12)
Invasive and In Situ	2.56 (2.53, 2.59)	2.94 (2.90, 2.97)	0.11 (0.09, 0.14)
Breast	12.29 (12.23, 12.36)	12.67 (12.59, 12.74)	10.58 (10.38, 10.77)
Invasive and In Situ	14.78 (14.71, 14.85)	15.16 (15.08, 15.24)	12.75 (12.54, 12.97)
Cervix Uteri	0.68 (0.67, 0.70)	0.66 (0.64, 0.68)	0.84 (0.79, 0.89)
Corpus and Uterus, NOS	2.61 (2.58, 2.64)	2.72 (2.69, 2.75)	2.10 (2.02, 2.19)
Invasive and In Situ	2.64 (2.61, 2.67)	2.75 (2.71, 2.78)	2.13 (2.04, 2.22)
Ovary[a]	1.40 (1.38, 1.43)	1.48 (1.45, 1.50)	0.99 (0.92, 1.05)
Urinary Bladder (Invasive and In Situ)	1.15 (1.13, 1.18)	1.23 (1.20, 1.25)	0.79 (0.73, 0.86)
Kidney and Renal Pelvis	1.19 (1.17, 1.21)	1.23 (1.21, 1.25)	1.17 (1.10, 1.24)
Brain and Other Nervous System	0.53 (0.52, 0.55)	0.58 (0.57, 0.60)	0.30 (0.27, 0.34)
Thyroid	1.44 (1.42, 1.46)	1.51 (1.49, 1.53)	0.79 (0.74, 0.84)
Hodgkin Lymphoma	0.21 (0.21, 0.22)	0.23 (0.22, 0.24)	0.18 (0.16, 0.20)
Non-Hodgkin Lymphoma	1.94 (1.92, 1.97)	2.05 (2.02, 2.08)	1.15 (1.08, 1.22)
Myeloma	0.56 (0.55, 0.58)	0.51 (0.49, 0.53)	1.04 (0.97, 1.10)
Leukemia	1.14 (1.12, 1.16)	1.19 (1.17, 1.21)	0.75 (0.70, 0.81)
Acute Lymphocytic Leukemia	0.11 (0.11, 0.12)	0.13 (0.12, 0.13)	0.05 (0.04, 0.07)
Chronic Lymphocytic Leukemia	0.40 (0.39, 0.41)	0.43 (0.41, 0.44)	0.20 (0.17, 0.23)
Acute Myeloid Leukemia	0.36 (0.35, 0.37)	0.36 (0.35, 0.38)	0.29 (0.26, 0.33)
Chronic Myeloid Leukemia	0.14 (0.13, 0.14)	0.14 (0.13, 0.15)	0.11 (0.09, 0.14)
Kaposi Sarcoma	0.01 (0.01, 0.02)	0.01 (0.01, 0.01)	0.02 (0.01, 0.03)
Mesothelioma	0.06 (0.05, 0.06)	0.06 (0.06, 0.07)	0.03 (0.02, 0.05)

Devcan Version 6.6.0, October 2011, National Cancer Institute (http://surveillance.cancer.gov/devcan/).
Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Note: Invasive cancer only unless specified otherwise.
[a] Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 17 SEER Areas, 2006-2008

Site	Asian/Pacific Islanders Percent (95% C.I.)	American Indian/ Alaska Natives[a] Percent (95% C.I.)	Hispanics[b] Percent (95% C.I.)
All Sites	33.67 (33.17, 34.19)	28.12 (26.57, 29.87)	34.69 (34.25, 35.14)
Invasive and In Situ	36.16 (35.65, 36.69)	29.24 (27.67, 31.00)	36.79 (36.34, 37.25)
Oral Cavity and Pharynx	0.61 (0.55, 0.70)	0.63 (0.36, 1.20)	0.51 (0.46, 0.58)
Esophagus	0.23 (0.18, 0.30)	0.38 (0.22, 0.86)	0.15 (0.13, 0.20)
Stomach	1.55 (1.43, 1.68)	0.77 (0.55, 1.28)	1.21 (1.12, 1.31)
Colon and Rectum	5.04 (4.83, 5.27)	4.21 (3.59, 5.06)	4.39 (4.22, 4.57)
Invasive and In Situ	5.21 (5.00, 5.44)	4.39 (3.76, 5.25)	4.57 (4.40, 4.76)
Liver and Intrahepatic Bile Duct	1.31 (1.20, 1.43)	0.85 (0.61, 1.37)	0.99 (0.91, 1.09)
Pancreas	1.62 (1.48, 1.77)	1.33 (1.00, 1.91)	1.66 (1.55, 1.79)
Larynx	0.05 (0.03, 0.10)	0.11 (0.04, 0.56)	0.07 (0.05, 0.10)
Invasive and In Situ	0.06 (0.03, 0.11)	0.12 (0.05, 0.57)	0.07 (0.06, 0.10)
Lung and Bronchus	4.39 (4.19, 4.60)	4.28 (3.68, 5.10)	3.66 (3.51, 3.82)
Melanoma of the Skin	0.13 (0.10, 0.18)	0.34 (0.21, 0.79)	0.50 (0.45, 0.55)
Invasive and In Situ	0.18 (0.15, 0.23)	0.46 (0.30, 0.92)	0.72 (0.66, 0.79)
Breast	9.91 (9.68, 10.15)	7.04 (6.36, 7.92)	9.73 (9.53, 9.95)
Invasive and In Situ	12.46 (12.21, 12.72)	8.02 (7.31, 8.93)	11.49 (11.27, 11.72)
Cervix Uteri	0.71 (0.65, 0.79)	0.60 (0.45, 1.06)	1.10 (1.04, 1.17)
Corpus and Uterus, NOS	1.98 (1.89, 2.09)	1.76 (1.44, 2.33)	2.13 (2.03, 2.23)
Invasive and In Situ	1.99 (1.90, 2.10)	1.76 (1.44, 2.33)	2.15 (2.05, 2.25)
Ovary[c]	1.15 (1.07, 1.25)	1.25 (0.93, 1.83)	1.38 (1.30, 1.47)
Urinary Bladder (Invasive and In Situ)	0.65 (0.57, 0.75)	0.45 (0.25, 0.96)	0.80 (0.72, 0.88)
Kidney and Renal Pelvis	0.78 (0.71, 0.87)	1.47 (1.15, 2.05)	1.36 (1.28, 1.45)
Brain and Other Nervous System	0.37 (0.31, 0.44)	0.29 (0.18, 0.74)	0.51 (0.47, 0.57)
Thyroid	1.61 (1.53, 1.70)	0.78 (0.60, 1.25)	1.40 (1.33, 1.48)
Hodgkin Lymphoma	0.10 (0.08, 0.14)	0.12 (0.03, 0.59)	0.21 (0.18, 0.25)
Non-Hodgkin Lymphoma	1.60 (1.48, 1.74)	1.11 (0.82, 1.67)	1.98 (1.88, 2.10)
Myeloma	0.41 (0.36, 0.48)	0.40 (0.25, 0.87)	0.60 (0.55, 0.67)
Leukemia	0.81 (0.73, 0.91)	0.57 (0.40, 1.05)	0.95 (0.89, 1.02)
Acute Lymphocytic Leukemia	0.10 (0.08, 0.14)	0.06 (0.02, 0.51)	0.19 (0.18, 0.23)
Chronic Lymphocytic Leukemia	0.13 (0.09, 0.19)	0.03 (0.00, 0.49)	0.20 (0.17, 0.25)
Acute Myeloid Leukemia	0.39 (0.34, 0.47)	0.30 (0.18, 0.76)	0.31 (0.27, 0.36)
Chronic Myeloid Leukemia	0.09 (0.07, 0.14)	0.09 (0.04, 0.54)	0.12 (0.10, 0.16)
Kaposi Sarcoma	0.00 (0.00, 0.05)	0.02 (0.00, 0.48)	0.02 (0.01, 0.05)
Mesothelioma	0.03 (0.02, 0.07)	0.07 (0.02, 0.53)	0.06 (0.05, 0.10)

Source: Devcan Version 6.6.0, October 2011, National Cancer Institute (http://surveillance.cancer.gov/devcan/).
SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

[a] Underlying incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

[b] Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

[c] Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.